SS Innovations International, Inc. (NASDAQ: SSII) – 2025 Annual Report: Key Investor Highlights

Overview

SS Innovations International, Inc. (“SSi” or “the Company”) has released its Annual Report for the year ended December 31, 2025. The report covers major financial, operational, and strategic developments that are crucial for investors and shareholders. The Company, listed on the Nasdaq since April 2025, is focused on developing, manufacturing, and marketing advanced surgical robotic systems and related technologies.

Key Financial Highlights

• Total Revenue: \$42.48 million in 2025, up from \$20.65 million in 2024 (growth of 106%).
• Gross Profit: Increased to \$19.54 million (2025) from \$8.45 million (2024).
• Net Loss: Reduced to \$12.13 million in 2025 from \$19.15 million in 2024.
• Shareholders’ Equity: \$38.2 million as of December 31, 2025, up from \$13.46 million at end of 2024.
• Cash & Cash Equivalents: \$9.60 million at year-end 2025 (\$3.21 million cash, \$6.40 million restricted cash).
• Working Capital Surplus: \$22.56 million at year-end 2025, a significant increase from \$6.09 million in 2024.
• Public Float: \$270.1 million as of the last business day of the second fiscal quarter of 2025.
• Shares Outstanding: 194,356,696 shares as of March 9, 2026 (plus 5,774,839 shares under issuance in connection with a recent private placement).

Major Corporate Developments & Potentially Price-Sensitive Events

1. Significant Private Placement Raises \$18.6 Million

• On March 6, 2026, SSi completed a private placement, generating gross proceeds of \$18,621,498. This is a substantial capital raise that will be used for working capital, accelerating growth initiatives in India and other existing global markets, and supporting market entry preparation for the United States and European Union.
• Details of the Placement:
  • 5,774,839 shares of common stock issued, including:
    • 1,300,006 shares at \$4.00 per share (total \$5,197,000) sold to directors:
      • 498,753 shares to Dr. Sudhir Srivastava, Chairman and CEO (\$2,000,000 at \$4.01/share)
      • 501,253 shares to Dr. Frederic Moll, Vice Chairman (\$2,000,000 at \$3.99/share)
      • 300,000 shares to Tim Adams, Director (\$1,197,000 at \$3.99/share)
    • 4,474,833 shares at \$3.00 per share to existing and new investors, led by Manipal Global Health Services (\$13,424,498)
  • Commission paid to a FINRA member firm: \$175,000 plus five-year warrants to purchase 41,667 shares at \$3.45/share for facilitating a \$2.5 million investment.
  • Within 90 days of the closing, SSi will file a registration statement to cover the resale of the shares by non-affiliate investors.
  • Securities in the offering were issued under Section 4(a)(2) and Rule 506(b) of Regulation D.

2. Improved Financial Performance and Reduced Losses

• While SSi remains unprofitable, net loss narrowed significantly (by over \$7 million) due to higher gross profits and lower stock-based compensation expenses.
• The Company’s cash position and equity base have strengthened, reducing liquidity risk and supporting ongoing operations and expansion plans.

3. Ongoing Capital Needs and Going Concern Warning

• Despite improved results, SSi continues to rely on external financing and may need to raise additional capital in 2026 through further private or public offerings.
• The Company’s financial statements include a going concern warning, as consistent operating revenue cash flows have not yet been established to cover fixed operating costs. If unable to secure further funding, the Company may be forced to limit expansion, R&D, or marketing activities.

4. Nasdaq Listing and Shareholder Structure

• SSi’s common stock began trading on Nasdaq on April 24, 2025, with the symbol “SSII.”
• As of the report date, there are 194.36 million shares outstanding (excluding new private placement shares), and approximately 303 holders of record, including CEDE & Company (which holds shares for brokerage clients).

5. Equity Compensation and Dilution

• Equity compensation remains a major part of SSi’s employee and management rewards:
  • 11,647,844 shares issued under the 2016 Incentive Stock Plan (7,739,432 options, 3,908,412 stock grants).
  • Weighted average exercise price: \$4.343/share.
  • 7,787,826 shares remain available for future issuance under compensation plans.
• Recent unregistered share issues (advisory services, warrant exercises) contribute to ongoing shareholder dilution.

6. Intellectual Property Portfolio

• As of the report date, SSi holds 15 granted utility patents, 70 pending utility patent applications, and 8 PCT international WIPO applications, underlining its commitment to innovation and competitive protection.

7. Risks and Forward-Looking Statements

• The Company’s report includes extensive forward-looking statements regarding future growth, regulatory approvals, global expansion, and R&D. These are subject to numerous uncertainties including market demand, funding, competition, regulatory risks, and general economic conditions.
• SSi is classified as a “smaller reporting company” and an “emerging growth company.”
• No dividends have been paid, and none are expected in the foreseeable future.

Potential Share Price Sensitivities

• Material capital raise and new share issuance may cause shareholder dilution but strengthens the balance sheet and supports operational expansion.
• Strong revenue growth and narrowing losses may signal improving fundamentals and could positively influence investor sentiment.
• Going concern warning remains a risk factor—future capital raises are critical for ongoing operations and growth.
• Commitment to expanding manufacturing, R&D, and market entry into the US/EU could be significant catalysts if milestones are met.
• Executive participation in the private placement at market-related prices may be viewed as a vote of confidence.

Summary Table: Selected Financial Data

View SS Innovations International, Inc. Historical chart here